Original ArticlePancreas, Biliary Tract, and LiverA High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury
Section snippets
Study Population
In this single-center cohort study, we prospectively recruited patients with a clinical diagnosis of DILI at Beijing Friendship Hospital, Capital Medical University, from August 2018 to August 2019.
The inclusion criteria were as follows: (1) Chinese Han nationality aged 18 to 78 years, (2) outpatients or inpatients with a diagnosis of DILI, and (3) available blood samples from the acute phase (within 10 days of obtaining the peak value of transaminase or bilirubin).
The exclusion criteria were
Clinical Characteristics of Drug-Induced Liver Injury Patients, Healthy Controls, and Chronic Hepatitis B Patients
This study included 95 DILI patients, 100 healthy controls (Figure 1), and 105 non-cirrhotic CHB patients. Age, gender, and BMI were comparable among 3 groups. The demographic, biochemical, and clinical characteristics are summarized in Table 1, Supplementary Tables 2 and 3.
The median age of DILI patients was 53 years, and the majority (73.7%) were female. On the basis of the R value, 63, 17, and 15 cases were defined as having a hepatocellular, cholestatic, and mixed phenotype, respectively.
Discussion
In this study we found that the levels of certain conjugated BAs increased in a stepwise manner along with DILI severity. Furthermore, the level of serum TCA was independently associated with the clinical resolution of DILI. The alteration of serum BAs was associated with reduced liver expression of BSEP but not with genetic variants of ABCB11, encoding BSEP. Taken together, these results suggest that a high serum TCA level is positively associated with disease severity and can potentially
Acknowledgments
The authors thank Wei Chen, Donghu Zhou, and Siyu Jia from Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China, for their help in the experiments and interpretation of the results, and Dr Ipsita Panda from India for her generous help in critical revision and language polishing.
CRediT Authorship Contributions
Qiuju Tian (Data curation: Lead; Formal analysis: Lead; Writing – original draft: Lead)
Ruiyuan Yang (Data curation: Lead; Formal analysis: Lead),
Yan Wang
References (36)
- et al.
Incidence of drug-induced hepatic injuries: a French population-based study
Hepatology
(2002) - et al.
Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury
Mod Pathol
(2019) - et al.
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury
J Hepatol
(2016) - et al.
Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition
Toxicol Appl Pharmacol
(2018) - et al.
Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats
Toxicology
(2017) - et al.
Biliary bile acids in hepatobiliary injury: what is the link?
J Hepatol
(2017) - et al.
Drug-induced liver injury: interactions between drug properties and host factors
J Hepatol
(2015) - et al.
Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland
Gastroenterology
(2013) - et al.
Incidence and etiology of drug-induced liver injury in mainland China
Gastroenterology
(2019) - et al.
Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements
Hepatology
(2017)
Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: rare but has severe consequences
Hepatology
Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry
Hepatology
Drug-induced liver injury: types and phenotypes
N Engl J Med
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Hepatol Int
ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Am J Gastroenterol
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Gut
A proposed pathologic sub-classification of drug-induced liver injury
Hepatol Int
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations
Hepatology
Cited by (15)
Study on the mechanism of Gao-Liang-Huo decoction against dextran sulfate sodium-induced ulcerative colitis based on metabolomics and network pharmacology
2023, Pharmacological Research - Modern Chinese MedicineInvestigating the inter-individual variability of Astragali Radix against cisplatin-induced liver injury via 16S rRNA gene sequencing and LC/MS-based metabolomics
2022, PhytomedicineCitation Excerpt :A previous study has evidenced TCA could promote liver cirrhosis both in vitro and in vivo (Liu et al., 2018). In addition, a prospective study of 95 patients with drug-induced liver injury (DILI) also found that the serum TCA was positively related to the severity of DILI (Tian et al., 2021). In this study, serum TCA in the CDDP group was increased significantly and could be decreased after AR administration (FC<0.8), which indicated that the liver-protective effect of AR was related to the regulation of taurine and hypotaurine metabolism and primary bile acid biosynthesis.
Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury
2024, Current Issues in Molecular BiologySerum Taurocholic Acid Levels Have Predictive Value for Adverse Maternal and Infant Outcomes in Pregnant Women with Intrahepatic Cholestasis of Pregnancy: A Prospective Cohort Study
2023, Clinical and Experimental Obstetrics and Gynecology
Conflicts of interest The authors disclose no conflicts.
Funding Suppported by grants from the National Natural Science Foundation of China (No. 81670545), the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (No. XXZ0301), the National Science and Technology Major Special Project for New Drug Development (No. 2018ZX09201016), and the Key Technical and Executive Measures to Improve Early Phase Clinical Trials on Innovative Drugs for Liver Diseases (No. Z191100007619037).
- a
Authors share co-first authorship.